A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of BJ-005 in patients with advanced solid tumor or lymphoma. BJ-005 is a recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal antibody (mAb) fused with a portion of the extracellular domain of human TGF-β receptor II (TGF-βRII).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Male or female ≥ 18 years.
  • Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.
  • Histologically or cytologically confirmed advanced solid tumors or lymphoma
  • Measurable or evaluable disease per RECIST v1.1.
  • ECOG performance status 0 or 1.
  • Life expectancy ≥ 3 months.
  • Adequate hepatic function.
  • Calculated creatinine clearance (CrCL) > 50 mL/min (Cockroft-Gault Equation).
  • Adequate Hematological function.
  • Prothrombin time, international normalized ratio or activated partial thromboplastin time < 1.5 × ULN.
  • Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy.

Exclusion Criteria:

  • Prior therapy with anti PD-L1/TGF?R? targeting treatment.
  • Symptomatic primary central nervous system (CNS) tumor of CNS metastases.
  • Uncontrolled hypertension.
  • Significant thrombotic or hemorrhagic events.
  • Prior CAR-T therapy
  • Severe cardiovascular disease.
  • Active infection requiring therapy
  • Active HIV, hepatitis B or hepatitis C virus.
  • Active tuberculosis.
  • Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to study entry.
  • Pregnant or breast-feeding females.
  • Active or history of autoimmune disease or inflammatory disorders.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/27/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Hani Babiker, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Mitesh Borad, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20531161

Mayo Clinic Footer